表皮生长因子受体酪氨酸激酶抑制剂治疗老年晚期非小细胞肺癌临床分析  

Epidermal growth factor receptor tyrosine kinase inhibitor in treatment of elderly patients with non-small-cell lung cancer

作　　者：农靖颖[1] 王敬慧[1] 杨新杰[1] 孙怡芬[1] 张新勇[1] 吴羽华[1] 李曦[1] 张卉[1] 秦娜[1] 张权[1] 张树才[1] 

机构地区：[1]首都医科大学附属北京胸科医院肿瘤内科,101149

出　　处：《中华全科医师杂志》2012年第3期221-223,共3页Chinese Journal of General Practitioners

摘　　要：对2006年2月至2010年9月收治的70例年龄≥65岁接受厄洛替尼或吉非替尼治疗的晚期非小细胞肺癌患者的疗效及安全性进行回顾性分析。总有效率31．4％（22／70），控制率84．3％（59／70），中位无进展生存期8．0个月，中位生存期13．5个月（P〈0．05），1年生存率54．3％（38／70）；女性的有效率（42．8％）和控制率（94．3％）优于男性（20．0％和74．3％）（P〈0．05），非吸烟和体力状况〈2分者预后好；不良反应主要为轻度皮疹及腹泻。Seventy patients with advanced non-small-cell lung cancer （NSCLC） aged 65 or above were treated with epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-TKI） erlotinib or gefitinibfrom February 2006 to September 2010. The efficacy and toxicities of treatment were retrospectively analyzed. The overall response rate and disease control rate were 31.4% and 84. 3% , respectively. The median progression-free survival time and median survival time were 8.0 months and 13.5 months, respectively（P 〈 0. 05 ）. One-year survival rate was 54. 3%. Response rate （ CR ＋ PR） （42.9%） and disease control rate（94. 3% ） in female patients were superior to males （ 20.0% and 74. 3% ） （ P 〈 0. 05 ）. Non-smoking and PS score 〈 2 were good predictors for survival. The side effects were generally mild and mainly were skin rash and diarrhea.

关 键 词：癌 非小细胞肺 受体 表皮生长因子酪氨酸激酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]